Literature DB >> 24438132

Targeted cancer therapies part 1 #276.

Helen Gharwan, Hunter Groninger.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24438132      PMCID： PMC3924821          DOI： 10.1089/jpm.2013.9452

Source DB:  PubMed          Journal:  J Palliat Med        ISSN： 1557-7740            Impact factor:   2.947


× No keyword cloud information.
  9 in total

Review 1.  Tyrosine kinases as targets for cancer therapy.

Authors:  Daniela S Krause; Richard A Van Etten
Journal:  N Engl J Med       Date:  2005-07-14       Impact factor: 91.245

2.  Oncogenic targets, magnitude of benefit, and market pricing of antineoplastic drugs.

Authors:  Eitan Amir; Bostjan Seruga; Joaquin Martinez-Lopez; Ryan Kwong; Atanasio Pandiella; Ian F Tannock; Alberto Ocaña
Journal:  J Clin Oncol       Date:  2011-05-23       Impact factor: 44.544

Review 3.  Management of adverse events of targeted therapies in normal and special patients with metastatic renal cell carcinoma.

Authors:  María José Méndez-Vidal; Esther Martínez Ortega; Alvaro Montesa Pino; Begoña Pérez Valderrama; Ruth Viciana
Journal:  Cancer Metastasis Rev       Date:  2012-09       Impact factor: 9.264

Review 4.  Cardiovascular safety of tyrosine kinase inhibitors: with a special focus on cardiac repolarisation (QT interval).

Authors:  Rashmi R Shah; Joel Morganroth; Devron R Shah
Journal:  Drug Saf       Date:  2013-05       Impact factor: 5.606

Review 5.  Tyrosine kinase inhibitors: their on-target toxicities as potential indicators of efficacy.

Authors:  Devron R Shah; Rashmi R Shah; Joel Morganroth
Journal:  Drug Saf       Date:  2013-06       Impact factor: 5.606

Review 6.  Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib.

Authors:  Adam D Lipworth; Caroline Robert; Andrew X Zhu
Journal:  Oncology       Date:  2009-11-16       Impact factor: 2.935

Review 7.  Targeted cancer therapy: conferring specificity to cytotoxic drugs.

Authors:  Ravi V J Chari
Journal:  Acc Chem Res       Date:  2007-08-18       Impact factor: 22.384

Review 8.  Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects.

Authors:  Jörg Thomas Hartmann; Michael Haap; Hans-Georg Kopp; Hans-Peter Lipp
Journal:  Curr Drug Metab       Date:  2009-06       Impact factor: 3.731

9.  Severe toxicity of skin rash, fever and diarrhea associated with imatinib: case report and review of skin toxicities associated with tyrosine kinase inhibitors.

Authors:  Xuan Huang; Samir Patel; Nasir Ahmed; Karen Seiter; Delong Liu
Journal:  Drug Des Devel Ther       Date:  2009-02-06       Impact factor: 4.162
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.